04.04.2023

Hackathon - March 2023

Read more
#

Ardigen's feed news

Hackathon - March 2023
04.04.2023
Hackathon - March 2023
Read more
Ardigen and DKFZ research groups are entering into a collaboration to evaluate the safety of TCR-based therapies (TCR-Ts)
7 March 2023
Ardigen and DKFZ research groups are entering into a collaboration to evaluate the safety of TCR-based therapies (TCR-Ts)
Read more
Ardigen at SLAS International Conference & Exhibition 2023
02.03.2023
Ardigen at SLAS International Conference & Exhibition 2023
Read more
Meet Ardigen phenAID platform
24.02.2023
Meet Ardigen phenAID platform
Read more
Ardigen at PMWC 2023
31.01.2023
Ardigen at PMWC 2023
Read more
Mariola Fotin-Mleczek, PhD, has joined Ardigen’s Scientific Board to support the drug discovery process for cancer immunology therapies
17.11.2022
Mariola Fotin-Mleczek, PhD, has joined Ardigen’s Scientific Board to support the drug discovery process for cancer immunology therapies
Read more
Ardigen supports JUMP-CP Consortium scaling up image-based drug discovery with the world’s largest public Cell Painting dataset
27 October 2022
Ardigen supports JUMP-CP Consortium scaling up image-based drug discovery with the world’s largest public Cell Painting dataset
Read more
Agnieszka Blum, MD, PhD has been promoted to the Management Board of Ardigen to strengthen drug discovery expertise.
25 October 2022
Agnieszka Blum, MD, PhD has been promoted to the Management Board of Ardigen to strengthen drug discovery expertise.
Read more
Prof. Dr. med. Michael Schmitt, MHBA has joined Ardigen's Scientific Board to support the development of AI platforms for cell therapy discovery.
14 September 2022
Prof. Dr. med. Michael Schmitt, MHBA has joined Ardigen's Scientific Board to support the development of AI platforms for cell therapy discovery.
Read more
Go up